CAR T cells for mantle cell lymphoma: Is it time to reshuffle the deck? Editorial

  


Authors: Sauter, C. S.; Brentjens, R. J.
Title: CAR T cells for mantle cell lymphoma: Is it time to reshuffle the deck?
Abstract: In the New England Journal of Medicine, Wang et al. report favorable ZUMA-2 trial results of CAR T cells for patients with relapsed and refractory mantle cell lymphoma following prior failed Bruton's tyrosine kinase inhibitor therapy, with an overall response rate of 93% and an expected safety profile. © 2020 Elsevier Inc.
Journal Title: Cancer Cell
Volume: 37
Issue: 6
ISSN: 1535-6108
Publisher: Cell Press  
Date Published: 2020-06-08
Start Page: 761
End Page: 763
Language: English
DOI: 10.1016/j.ccell.2020.05.015
PUBMED: 32516587
PROVIDER: scopus
DOI/URL:

https://www.scopus.com/inward/record.uri?eid=2-s2.0-85085756185&doi=10.1016%2fj.ccell.2020.05.015&partnerID=40&md5=9e739f00a6680037d7e60f348d2f8b31
Notes: Article -- Export Date: 3 August 2020 -- Source: Scopus
Altmetric
What is Altmetric?
Citation Impact
What is Dimensions Citation Badge?
BMJ Impact Analytics
MSK Authors
  1. Renier J Brentjens
    286 Brentjens
  2. Craig Steven Sauter
    334 Sauter
Related MSK Work